Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
|3||Active, not recruiting||
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Dovitinib for Gastric Cancer With FGFR2 Amplification
|5||Not yet recruiting||
Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer
† Study has passed its completion date and status has not been verified in more than two years.